The HLA-A11 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the cDNA clone of the human HLA-A*1101 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains. This transgene was microinjected into CxB6 zygotes. The resultant mice from Founder Line A11.01 were backcrossed six generations to C57BL/6J. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived, backcrossed one generation to C57BL/6NTac and then intracrossed to homozygosity. In the production colony, wild type BALB/cAnNTac females are bred to homozygous males on the C57BL/6 background to produce CB6F1 pups.
Alexander J, Oseroff C, Sidney J, Wentworth P, Keogh E, Hermanson G, Chisari FV, Kubo RT, Grey HM, Sette A. (1997) Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol 159(10):4753-61. Erratum in: J Immunol 1999 162(5):3104.